ARWR logo

ARWR
Arrowhead Pharmaceuticals Inc.

12,396
Mkt Cap
$8.09B
Volume
1.65M
52W High
$76.76
52W Low
$9.57
PE Ratio
37.56
ARWR Fundamentals
Price
$57.78
Prev Close
$60.77
Open
$60.29
50D MA
$62.92
Beta
1.55
Avg. Volume
3.65M
EPS (Annual)
-$0.0122
P/B
13.97
Rev/Employee
$1.17M
$4,464.99
Loading...
Loading...
News
all
press releases
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiologys 75th Annual Scientific Session and Expo
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It?
Leerink analyst Mani Foroohar said that they are not surprised to see Arrowhead Pharmaceuticals’ stock down as material obesity value is baked in at the company’s $8.5 billion market cap.
Stocktwits·3d ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down - What's Next?
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down - Here's What Happened...
MarketBeat·3d ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday...
MarketBeat·4d ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.6% - Here's What Happened
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 8.6% - Time to Buy...
MarketBeat·4d ago
News Placeholder
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Nordea Investment Management AB
Nordea Investment Management AB lowered its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 12.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 324,251 shares of the biotechnology comp...
MarketBeat·5d ago
News Placeholder
Assenagon Asset Management S.A. Purchases 304,264 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
Assenagon Asset Management S.A. raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 79.9% during the fourth quarter, according to the company in its most recent...
MarketBeat·5d ago
News Placeholder
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning Anti-Aging Protein Research Takes a Step Forward with Cell Cloning PR Newswire VANCOUVER, BC, March 24, 2026 Issued on behalf of Ava...
PR Newswire·5d ago
News Placeholder
JPMorgan Chase & Co. Grows Stake in Arrowhead Pharmaceuticals, Inc. $ARWR
JPMorgan Chase & Co. grew its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 90.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 775,717 shares of the biotechnology company's stock after buying an additional 3...
MarketBeat·6d ago
News Placeholder
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP reduced its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 65.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 90,000 shares of the biotechnology company's st...
MarketBeat·8d ago
<
1
2
...
>

Latest ARWR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.